Pages that link to "Q35206324"
Jump to navigation
Jump to search
The following pages link to High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. (Q35206324):
Displaying 50 items.
- Hepatic steatosis: a benign disease or a silent killer (Q22305506) (← links)
- Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment (Q26775018) (← links)
- Hepatitis C virus infection and type 1 and type 2 diabetes mellitus (Q26829202) (← links)
- Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 (Q27478313) (← links)
- STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (Q27478329) (← links)
- Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis (Q27480999) (← links)
- Treatment responses in Asians and Caucasians with chronic hepatitis C infection (Q27489011) (← links)
- Managing chronic hepatitis C in the difficult-to-treat patient (Q27490409) (← links)
- Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment (Q27490841) (← links)
- Obesity and infection (Q28247492) (← links)
- Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3 (Q28729225) (← links)
- Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations (Q30733177) (← links)
- Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data (Q30892564) (← links)
- High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. (Q33788303) (← links)
- Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C. (Q33797446) (← links)
- Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection (Q34023077) (← links)
- Treatment of hepatitis C virus infection (Q34099424) (← links)
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection (Q34168383) (← links)
- Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome (Q34225234) (← links)
- Non-alcoholic fatty liver disease: an emerging pathological spectrum (Q34285124) (← links)
- Evolution of interferon-based therapy for chronic hepatitis C. (Q34342092) (← links)
- Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. (Q34365442) (← links)
- Review: Predicting the probable outcome of treatment in HCV patients (Q34409039) (← links)
- A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection (Q34432191) (← links)
- The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance (Q34469210) (← links)
- Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy (Q34621423) (← links)
- The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients (Q34996746) (← links)
- Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention (Q35105334) (← links)
- Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy (Q35237179) (← links)
- Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease (Q35237341) (← links)
- Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation (Q35621603) (← links)
- Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture (Q35626712) (← links)
- Fat, diabetes, and liver injury in chronic hepatitis C. (Q35628100) (← links)
- Host factors and failure of interferon-alpha treatment in hepatitis C virus (Q35730979) (← links)
- Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. (Q35740155) (← links)
- Management of chronic hepatitis C virus infection: a new era of disease control (Q35823410) (← links)
- When to treat patients with chronic hepatitis C. (Q35831941) (← links)
- Hepatitis C: How should we manage the patient? (Q35882856) (← links)
- Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice (Q36003873) (← links)
- Treatment of hepatitis C: critical appraisal of the evidence. (Q36082056) (← links)
- Steatosis: co-factor in other liver diseases. (Q36165987) (← links)
- Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study (Q36238748) (← links)
- Is liver disease a threat to patients with metabolic disorders? (Q36265230) (← links)
- Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications (Q36286318) (← links)
- Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients (Q36327795) (← links)
- Impact of obesity on treatment of chronic hepatitis C. (Q36490255) (← links)
- Improving anti-hepatitis C virus therapy (Q36569749) (← links)
- Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? (Q36587716) (← links)
- Histological assessment of non-alcoholic fatty liver disease (Q36634377) (← links)
- Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection (Q36667084) (← links)